Evidence map›Paper›PMID 28622068›Full record

ArticleCell cycle (Georgetown, Tex.)2017

Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.

Kei Kawaguchi, Kentaro Igarashi, Takashi Murakami, Tasuku Kiyuna, Ming Zhao, Yong Zhang, Scott D Nelson, Tara A Russell, Sarah M Dry, Arun S Singh and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Pharmaceutics · 2022
    Review
  4. Recombinant AttenuatedCancers · 2022
    Review
  5. Review
  6. Article
  7. HDrug design, development and therapy · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Journal of Cancer · 2019
    Review
  12. Article
  13. Article
  14. Tumor-targetingHeliyon · 2018
    Article
  15. On the role of classical and novel forms of vitamin D in melanoma progression and management.The Journal of steroid biochemistry and molecular biology · 2018
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Kei Kawaguchia AntiCancer, Inc. , San Diego , CA , USA.
Kentaro Igarashia AntiCancer, Inc. , San Diego , CA , USA.
Takashi Murakamia AntiCancer, Inc. , San Diego , CA , USA.
Tasuku Kiyunaa AntiCancer, Inc. , San Diego , CA , USA.
Ming Zhaoa AntiCancer, Inc. , San Diego , CA , USA.
Yong Zhanga AntiCancer, Inc. , San Diego , CA , USA.
Scott D Nelsond Department of Pathology , University of California , Los Angeles , CA , USA.
Tara A Russelle Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID http://orcid.org/0000-0002-3912-3601
Sarah M Dryd Department of Pathology , University of California , Los Angeles , CA , USA.
Arun S Singhf Division of Hematology-Oncology , University of California , Los Angeles , CA , USA.
Bartosz Chmielowskif Division of Hematology-Oncology , University of California , Los Angeles , CA , USA.ORCID http://orcid.org/0000-0002-2374-3320
Yunfeng Lid Department of Pathology , University of California , Los Angeles , CA , USA.
Michiaki Unnoc Department of Surgery, Graduate School of Medicine , Tohoku University , Sendai , Japan.
Fritz C Eilbere Division of Surgical Oncology , University of California , Los Angeles , CA , USA.ORCID http://orcid.org/0000-0003-3336-9333
Robert M Hoffmana AntiCancer, Inc. , San Diego , CA , USA.
University of California, Los Angeles · USUniversity of California San Diego · USAntiCancer (United States) · USTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A metastatic melanoma obtained from the right chest wall of a patient was previously established orthotopically in the right chest wall of nude mice as a patient-derived orthotopic xenograft (PDOX) model. We previously showed that the combination of tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) and chemotherapy was highly effective against the melanoma PDOX. In the present study, we investigated the mechanism of the high efficacy of this combination. Two weeks after implantation, 40 PDOX mouse models were randomized into 4 groups of 10 mice each: untreated control (n = 10); treated with S. typhimurium A1-R (5 × 10

Indexed as

AgedAnimalsAntineoplastic AgentsDacarbazineDisease Models, AnimalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHeterograftsHumansIndolesMelanomaMiceMice, NudeMicroscopy, ConfocalProto-Oncogene Proteins B-rafAntineoplastic AgentsBRAF protein, humanDacarbazineIndolesProto-Oncogene Proteins B-rafSulfonamidesTemozolomideVemurafenibcombination therapydrug-responsemelanomanude miceorthotopicPDOXprecision therapySalmonella typhimurium A1-Rtemozolomidetumor regressionvemurafenib

Identifiers

PMID28622068
PMCPMC5531627
OpenAlexW2626307008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.